Osiris Therapeutics (OTCMKTS: OSIR) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Valuation & Earnings

This table compares Osiris Therapeutics and Trillium Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $59.87 million 3.19 -$1.78 million N/A N/A
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -2.36

Osiris Therapeutics has higher revenue and earnings than Trillium Therapeutics.

Profitability

This table compares Osiris Therapeutics and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics N/A N/A N/A
Trillium Therapeutics N/A -248.39% -65.21%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Osiris Therapeutics and Trillium Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Trillium Therapeutics 0 0 3 0 3.00

Trillium Therapeutics has a consensus target price of $12.50, indicating a potential upside of 39.66%. Given Trillium Therapeutics’ higher possible upside, analysts plainly believe Trillium Therapeutics is more favorable than Osiris Therapeutics.

Insider and Institutional Ownership

0.3% of Osiris Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Trillium Therapeutics shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Osiris Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Summary

Osiris Therapeutics beats Trillium Therapeutics on 5 of the 9 factors compared between the two stocks.

Osiris Therapeutics Company Profile

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.